Argireline in Treatment of Periorbital Wrinkles
Efficacy and Safety of Topical Argireline in the Treatment of Periorbital Wrinkles
1 other identifier
interventional
70
1 country
1
Brief Summary
The purpose of this study is to determine whether La Jolie gel is effective in the treatment of periorbital wrinkles.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
Started Mar 2009
Shorter than P25 for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2009
CompletedFirst Submitted
Initial submission to the registry
March 30, 2011
CompletedFirst Posted
Study publicly available on registry
June 27, 2011
CompletedJune 27, 2011
March 1, 2011
6 months
March 30, 2011
June 23, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Efficacy
Objective evaluation * Noninvasive measurement by skin bioengineering technique e.g. visioscan, corneometer, cutometer * Comparative photographic evaluation by certified dermatologists Subjective evaluation * Patient Self assessment satifaction review
3 months
Secondary Outcomes (1)
Safety
3 months
Study Arms (2)
Placebo
NO INTERVENTIONThis group received placebo gel and requested to apply periorbital area and over the face for 3 months.
Study group
EXPERIMENTALThis group received La Jolie Gel and requested to apply periorbital area and over the face for 3 months.
Interventions
10% Argireline (La jolie gel®, Pacific health care, Thailand) were instructed to apply the gel over the face and periorbital area twice daily for a period of 3 months.
Eligibility Criteria
You may qualify if:
- healthy woman at 35-45 years old
- Presence of periorbital wrinkles
You may not qualify if:
- Pregnancy
- Nursing
- Keloids /scar at periorbital area
- pre-treatment with topical periorbital products within 1 month
- Botulinum toxin A injection,facial plastic surgery within 1 year
- Allergic to active ingredients including acetyl hexapeptide-3 Argireline®, sodium hyaluronate,adenosine,arbutin,fucus vesiculosus)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mahidol Universitylead
- Pacific Health Foundationcollaborator
Study Sites (1)
Department of dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University
Bangkoknoi, Bangkok, 10700, Thailand
Related Publications (10)
Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernandez-Ballester G, Ponsati B, Gutierrez L, Perez-Paya E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002 Oct;24(5):303-10. doi: 10.1046/j.1467-2494.2002.00153.x.
PMID: 18498523BACKGROUNDTokiwa Y, Kitagawa M, Raku T, Yanagitani S, Yoshino K. Enzymatic synthesis of arbutin undecylenic acid ester and its inhibitory effect on melanin synthesis. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3105-8. doi: 10.1016/j.bmcl.2007.03.039. Epub 2007 Mar 16.
PMID: 17418566BACKGROUNDFarage MA, Miller KW, Elsner P, Maibach HI. Intrinsic and extrinsic factors in skin ageing: a review. Int J Cosmet Sci. 2008 Apr;30(2):87-95. doi: 10.1111/j.1468-2494.2007.00415.x.
PMID: 18377617RESULTKlein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg. 2003 May;29(5):549-56; discussion 556. doi: 10.1046/j.1524-4725.2003.29129.x. No abstract available.
PMID: 12752527RESULTBrown MB, Jones SA. Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. J Eur Acad Dermatol Venereol. 2005 May;19(3):308-18. doi: 10.1111/j.1468-3083.2004.01180.x.
PMID: 15857456RESULTAbella ML. Evaluation of anti-wrinkle efficacy of adenosine-containing products using the FOITS technique. Int J Cosmet Sci. 2006 Dec;28(6):447-51. doi: 10.1111/j.1467-2494.2006.00349.x.
PMID: 18489289RESULTSenni K, Gueniche F, Foucault-Bertaud A, Igondjo-Tchen S, Fioretti F, Colliec-Jouault S, Durand P, Guezennec J, Godeau G, Letourneur D. Fucoidan a sulfated polysaccharide from brown algae is a potent modulator of connective tissue proteolysis. Arch Biochem Biophys. 2006 Jan 1;445(1):56-64. doi: 10.1016/j.abb.2005.11.001. Epub 2005 Nov 28.
PMID: 16364234RESULTNarins RS, Brandt F, Leyden J, Lorenc ZP, Rubin M, Smith S. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg. 2003 Jun;29(6):588-95. doi: 10.1046/j.1524-4725.2003.29150.x.
PMID: 12786700RESULTRohrich RJ. The increasing popularity of cosmetic surgery procedures: a look at statistics in plastic surgery. Plast Reconstr Surg. 2000 Nov;106(6):1363-5. doi: 10.1097/00006534-200011000-00023. No abstract available.
PMID: 11083570RESULTManaloto RM, Alster TS. Periorbital rejuvenation: a review of dermatologic treatments. Dermatol Surg. 1999 Jan;25(1):1-9. doi: 10.1046/j.1524-4725.1999.08049.x.
PMID: 9935084RESULT
MeSH Terms
Interventions
Study Officials
- PRINCIPAL INVESTIGATOR
Supenya varothai, M.D.
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
March 30, 2011
First Posted
June 27, 2011
Study Start
March 1, 2009
Primary Completion
September 1, 2009
Study Completion
September 1, 2009
Last Updated
June 27, 2011
Record last verified: 2011-03